Agendia is launching a patient access program to position MammaPrint in clinics, while other test makers are taking a wait-and-see approach.
The acquisition provides Myriad with the EndoPredict test, which is currently offered in Europe and is expected to launch in the US next year.
The analysis showed that one out of 227 node-negative breast cancer patients with the lowest EPclin scores by Sividon's EndoPredict test experienced recurrence over 10 years.
At the San Antonio Breast Cancer Symposium, a Sividon collaborator is scheduled to present a new study including a comparison between EndoPredict and Oncotype DX.
National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.
NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.
The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.
In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.